PharmEasy Writes Health Minister For Final Rules Notification

New Delhi : API Holdings, the parent of PharmEasy, has sought the Union health minister’s intervention for quick notification of the draft e-pharmacy rules to remove regulatory uncertainty regarding their existence after the Drug Controller General of India (DCGI) issued show-cause notices to these platforms over online sale of drugs citing violation of norms.

In a letter written to the health Minister Mansukh Mandaviya, API Holdings asked for an urgent meeting with the delegation of online pharmacies to iron out issues.

“We seek your support towards the quick notification of the draft epharmacy rules and the New Drugs, Medical Devices and Cosmetics Bill 2022 to remove any uncertainty and to harmonise all the existing regulations under which the e-pharmacy is already compliant,” the letter said.

The government has proposed a draft legislation on multiple occasions, but it has yet to frame one.

In 2018 too, the health ministry had released a draft notification regulating e-pharmacies that barred the selling of medicines without registration. It banned the sale of narcotics, psychotropic drugs and tranquillisers by online pharmacies. But the rules could never be finalised.

In March this year, the department-related parliamentary committee on commerce urged the ministry of health and family welfare to notify the draft e-pharmacy rules. It said it was “appalled” that the rules had not been finalised till date.

The committee, headed by Congress leader Abhishek Manu Singhvi, said while tabling the report on ‘Promotion and Regulation of E-Commerce in India’ that undue delay in adopting a definitive regulatory framework results in uncertainty, which is not conducive for the fast-paced digital markets. It recommended that the draft e-pharmacy rules be finalised and implemented without further delay.

Retail chemist organisations have been protesting the sale of online medicines through e-pharmacies as they are not currently regulated.

Calling it a “strong pillar” to significantly improve access to affordable medicines, API Holdings said the sector provides “quality” and “affordable” medicines to about 100 million families across the country and employment to about 150,000 skilled professionals.

“The negative narrative questioning the legitimacy of the e-pharmacy model has created chaos among the 1.5 lakh professionals employed by e-pharmacies,” said API Holdings.

SOURCE : ET HealthWorld
  • Related Posts

    Diabetic drug metformin found to act on brain

    NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

    Hetero debuts semaglutide generic in emerging markets

    New Delhi: Hyderabad-based drugmaker Hetero has announced the launch of its generic semaglutide portfolio in emerging international markets. In a phased global push, the company plans to roll out its…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework